Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme - Moehler, M; Maderer, A; Schimanski, C (Eur J Cancer, 2014)
et al.